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Background | Alzheimer’s disease is the most 
common form of dementia for people aged 65 and over 
(Mayo Clinic, 2011). There were 5 million Americans 
living with Alzheimer’s disease (AD) in 2013, and this 
number may triple to 14 million by 2050 (Centers for 
Disease Control and Prevention, 2015). The Centers 
for Disease Control and Prevention (2015) reported 
that AD was the sixth leading cause of death among 
U.S. adults, yet this number was shown to be 
underreported (James et al., 2014; Weuve et al., 2014). 
The estimated costs of AD were more than 159 billion 
dollars in 2010, and are projected to be over 379 
billion dollars annually by 2040 (Centers for Disease 
Control and Prevention, 2015). The high mortality rate 
and huge expenditures caused by AD makes it a 
pressing concern for many researchers and the public 
health community. 
      
On the other hand, the prevalence of comorbidities in 
U.S. population is also high and growing (Vogeli et al, 
2007). Ward et al. (2013, 2014) estimated that the 
prevalence of multiple chronic diseases in U.S. adults 
is 26% in 2010, and 25.5% in 2012 based on data from 
the National Health Interview Survey (NHIS). In 
particular, the prevalence of comorbidities among 
Medicare beneficiaries is profoundly high — Lochner 
et al. (2013) reported that 68.4% of Medicare 
beneficiaries had multiple chronic diseases in 2010, 
i.e., 2.6 times of that for general U.S. adults (Ward et 
al., 2014) in the same year. 
 
In spite of the fact that extensive research has been 
conducted on the screening, diagnostic, prevention, 
treatment, quality of care, and prevalence of AD, 
comorbidities associated with AD are relatively less 
studied. For elders, AD is commonly associated with 
several chronic conditions. Some of these conditions 
may accelerate clinical development of AD and 
complicate the management (Solomon, 2011). For 
these reasons, an investigation of comorbidities with 
AD is especially important to improve the quality of 
long-term care for AD patients.  
 
Purpose | Preliminary studies showed that the etiology 
of dementia differs by race (Miles et al., 2001). Florida 
is the third-most populous state in the country (U.S. 
Comorbidity associated with Alzheimer’s Disease (AD) is highly prevalent but 
largely understudied. In this study, we sought to determine 1) the prevalence 
of AD by race (White, African American, and Hispanics); 2) 20 chronic 
conditions’ commonly comorbid with AD and the prevalence, mortality rate, 
and health care expenditure of common AD and comorbid condition by race. 
A sample of 86,875 Florida 2010 Medicare beneficiaries aged 65 and older 
with 12 months of fee-for-service (FFS) enrollment were used in this study. In 
the present analysis, the prevalence of AD was highest among elderly Hispanic 
beneficiaries. Among 20 chronic diseases, heart disease (Heart Failure, 
Ischemic Heart Disease, Atrial Fibrillation) were the most prevalent, most 
deadly, and most costly comorbidities associated with AD. Hypertension and 
Hyperlipidemia were highly prevalent comorbidities. Persons with AD had an 
increased risk of depression. Persons with AD and Chronic Kidney Disease 
were associated with a high likelihood of mortality and high health care costs. 
Hip Fracture was one of the most costly comorbid conditions, and was also 
associated with a high mortality rate for Whites and Hispanics. The results 
revealed a comprehensive picture of certain comorbid conditions associated 
with AD and suggested the need for further investigation in this area. 
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Census Bureau, 2014) with a wide variety of racial and 
ethnic backgrounds, which makes research on how the 
prevalence of comorbidities among Florida Medicare 
beneficiaries differs by race of interest. In addition, 
Florida contains the highest percentage of people over 
65 (U.S. Census Bureau, 2011). Therefore, an 
investigation of the comorbidity associated with AD 
and the corresponding health care cost could improve 
planning for the Florida health system in the long term. 
 
In this study, we examined the demographic 
characteristics of Medicare participants in Florida. 
Specifically, we compared the differences in co-
existing chronic diseases among White, African-
American, and Hispanic beneficiaries with AD. To our 
best knowledge, no such studies have been published 
before.  
 
Methods | STUDY DESIGN. This retrospective study 
examined 86,875 White, African American, and 
Hispanic Florida 2010 Medicare beneficiaries aged 65 
and over who had full FFS coverage (i.e. 12 months of 
Medicare Part A and B), using a 5% sample of 
Medicare FFS claim data. 
 
SETTING. Medicare is a U.S. government health 
insurance program for people who are 65 or older and 
disabled people under 65. This study used the 2010 
national Medicare claim data from six sources: carrier, 
inpatient, outpatient, skilled nurse facility (SNF), 
hospice, and home health agency (HHA). Prescription 
drug data were not available. The original data from 
Carrier provided records of a 5% sample of U.S. 
Medicare beneficiaries. The carrier file sample was 
linked with the 100% files from the other five sources 
and the denominator file to create a 5% sample of 
Florida 2010 beneficiaries. 
 
STUDY POPULATION. Our analyses were based 
on data from a 5% sample consisting of 1,711,151 U.S. 
national Medicare participants in 2010. Of these 
eligible participants, 86,875 subjects were selected as 
the final study sample based on the following 
exclusion steps: 1) subjects with duplicates or 
inconsistent records were excluded; 2) subjects with 
less than 12 months in the traditional FFS Medicare, 
less than 65 years of age, and non-Florida residents 
were excluded; 3) Asian, North American Native, and 
subjects with other or unknown races were excluded 
due to small sample size. See Figure 1 for study 
population flow chart. 
 
The final study sample consisted of 86,875 
individuals, with age of mean and standard deviation 
(SD) of 76 (±7.8). 
 
MEASURES. Persons with one or more of 21 chronic 
diseases: Alzheimer's Disease (AD), Acquired 
Hypothyroidism, Ischemic Heart Disease, Cancer 
(including Breast Cancer, Colorectal Cancer, Prostate 
Cancer, Lung Cancer, Endometrial Cancer), Anemia, 
Asthma, Atrial Fibrillation, Benign Prostatic 
Hyperplasia, Cataract, Chronic Kidney Disease, 
Chronic Obstructive Pulmonary Disease (COPD) and 
Bronchiectasis, Depression, Diabetes, Glaucoma, 
Heart Failure, Hip Fracture, Hyperlipidemia, 
Hypertension, Osteoporosis, RA/OA (Rheumatoid 
Arthritis/ Osteoarthritis), and Stroke/ Transient 
Ischemic Attack were identified. Indicator variables 
were created to identify the diagnosis of these 
conditions based on ICD9-codes from claim records, 
using the disease identification algorithm provided by 
Chronic Condition Data Warehouse (CCW, 2014). 
Each beneficiary may have up to 21 comorbid 
diagnoses.  
 
Another outcome variable of interest was health care 
expenditure. A new variable was constructed to 
compute the total expenditure for each subject as the 
sum of amounts of payments made by Medicare, 
secondary insurance, and beneficiary.  
 
Demographic variables included age, sex, race, vital 
status (live/dead), and state Medicaid buy-in status. 
The vital status was constructed based on the variable 
of date of death in the original data. A state Medicaid 
buy-in insurance indicator was constructed based on 
the Medicaid buy-in variable with one or more 
months. 
 
DATA ANALYSIS. Statistical tests were applied to 
access differences in sample characteristics across 
race and ethnic groups, with 𝜒#	 test for qualitative 
variables and ANOVA test for continuous variables. 
Data analysis was performed using SAS version 9.4. 
All analyses were stratified by race. 
 
Results | Table 1 presents demographic characteristics 
of the study sample. Beneficiaries were more likely to 
be female (56.9%), White (90.6%), and between 65 
and 74 years old (48.7%). Among 86,875 Medicare 
beneficiaries aged 65 and over in Florida, 2010, 6.8% 







Florida Public Health Review, Vol. 17 [], Art. 1
https://digitalcommons.unf.edu/fphr/vol17/iss1/1
 
HU & CARRETTA 3 
 
Table 1. Sample characteristics in Florida Medicare Beneficiaries, 2010 (N=86,875) 
 n % 
Female 49429 56.9 
Age (years)   
  65-74 42346 48.7 
  75-84 30651 35.3 
  ≥85 13878 16 
Race   
  White 78725 90.6 
  African American 5049 5.8 
  Hispanic 3101 3.6 
Alzheimer’s Disease 5879 6.8 
Mortality 5274 6.1 
State Medicaid Buy-In Insurance Status 11433 13.2 
 
Table 2 presents demographic characteristics of the 
study sample by race. The average and standard error 
(SE) of age was 76 (±7.7), 75(±7.7), 78(±8.1) (data 
not shown) for White, African American, and 
Hispanic participants respectively (data not shown). 
There were statistically significant differences in 
gender, age group, AD presence, mortality, and state 
Medicaid buy-in insurance status between three race  
groups (p < 0.01). Beneficiaries were more likely to 
be female and 65-74 years of age regardless of race 
groups. Compared to White and African Americans, 
Hispanics were more likely to be older, female, and 
insured. More importantly, Hispanics were at higher 
risk of AD (18.7%) than White (6.2%) and African 
Americans (7.8%).%).  








Female 44303 (56.3) 3032 (60.1) 2094 (67.5) 174.75a ** 
Age (years)    205.88b ** 
  65-74 38292 (48.6) 2798 (55.4) 1256 (40.5)   
  75-84 27872 (35.4) 1603 (31.8) 1176 (37.9)   
  ≥85 12561 (16.0) 648 (12.8) 669 (21.6)   
Alzheimer’s Disease 4904 (6.2) 394 (7.8) 581 (18.7) 748.77a ** 
Mortality 4707 (6.0) 345 (6.8) 222 (7.2) 12.75a * 
State Medicaid Buy-in      
Insurance Status 6994 (8.9) 1947 (38.6) 2492 (80.4) 16364.05a ** 
Notes: 
$ Based on Chi-square test. 
a 2 degrees of freedom (df); b 4 df; 
*=p<0.01; **=p<0.0001 
 
Table 3 compares mean count of chronic conditions, 
mean health care expenditure, and the mortality rate 
by race between the entire sample of 86,875 Florida 
2010 FFS elder Medicare beneficiaries and the 
subsample of 5,879 beneficiaries with AD. The 
results in Table 3 shows that beneficiaries with AD 
had two more conditions on average than 
beneficiaries in general. Beneficiaries with AD also 
cost more on average, and had a higher mortality rate, 
compared to beneficiaries in general. Among the 
beneficiaries with AD, White had a slightly higher 
(see Table 3) mortality rate than African American 
and Hispanic, in spite of a lower prevalence rate (see 
Table 2). This finding is in line with the review of 
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Table 3. Comparisons of mean count of chronic conditions, mean cost, and mortality rate by race between two 
samples. 
 All Beneficiaries in the sample (N=86,875) Beneficiaries with AD in the sample 
(N=5,879) 
 All White African 
American 





4.6 4.5 4.8 6 6.8 6.6 6.9 7.9 
Mean 
expenditures 
$12,717 $12,349 $15,204 $18,027 $25,517 $24,927 $27,919 $28,873 
Mortality rate 6% 6% 6.8% 7.2% 22.1% 22.7% 21.2% 17.4% 
 
Table 4 listed top five co-existing diseases associated 
with highest risk of AD between three race groups, 
ranked by odds ratio (OR) for AD. There were four 
diseases in common for three race groups: Hip 
Fracture, Heart Failure, Anemia, and Depression. 
However, the level of AD risk associated with each 
disease might differ by race. From Table 4, Heart 
Failure was associated with similar levels of risk for 
AD between Whites, African Americans and 
Hispanics (2.77 (2.6, 2.94), 2.32 (1.88, 2.87), 2.21 
(1.84, 2.67)); so was Anemia (OR=2.76 (2.61, 2.93),  
2.77 (2.23, 3.43), 2.3(1.91, 2.77)). Depression was 
associated with a higher risk of AD for Whites 
(OR=4.8 (4.51, 5.12)) and African Americans 
(OR=4.95(3.92, 6.25)) than for Hispanics (OR=2.56 
(2.13, 2.77)). Hip Fracture was significantly 
associated with a high risk of AD for White (5.26 
(4.49, 6.18)) and Hispanic (OR=4.1 (1.92, 8.76)), but 
not for African American (OR=2.12 (0.29, 15.57), 
data not shown); the reason is to be further 
investigated.  
Table 4. AD co-existing diseases with the highest odds ratio by race in Florida Medicare Beneficiaries 
(N=86,875), 2010 




OR (95% CI) Co-existing 
Disease 
OR (95% CI) Co-existing 
Disease 
OR (95%) 
1 Hip Fracture 5.26 (4.49, 6.18) Depression 4.95 (3.92, 6.25) Hip Fracture 4.1 (1.92, 8.76) 
2 Depression 
4.8 (4.51, 5.12) 
Stroke/ Transient 
Ischemic Attack 4.09 (3.16, 5.29) Depression 2.56 (2.13, 3.08) 
3 Heart Failure 2.77 (2.6, 2.94) Anemia 2.77 (2.23, 3.43) Anemia 2.3 (1.91, 2.77) 
4 Anemia 2.76 (2.61, 2.93) Heart Failure 2.32 (1.88, 2.87) Heart Failure 2.21 (1.84, 2.67) 
5 Stroke/Transient 
Ischemic Attack 2.75 (2.51, 3.02) Hip Fracture 2.12 (0.29, 15.57) 
Ischemic 
Heart Disease 2.08 (1.69, 2.54) 
Notes: AD: Alzheimer's Disease. OR: Odds ratio. CI: confidence interval.   
# Rank is based on odds ratio for AD given presence of a second disease. An individual record may have up to 20 second 
diseases. 
 
Tables 5-7 refer only to the subsample of 5,879 
Florida older Medicare beneficiaries with AD. Table 
5 lists the five most frequent co-existing diseases 
among 5,879 Florida Medicare beneficiaries with AD 
by race. Four diseases in common for three race 
groups were Hypertension, Ischemic Heart Disease, 
Anemia, and Hyperlipidemia. Among these diseases, 
Hypertension was more common among African 
American (82%) and Hispanic (86.4%) AD patients 
than among White (76.5%), so was Anemia (64%, 
63.7%, 54.9%). Ischemic Heart Disease was more 
common among Hispanic AD patients (75%), than 
among White (60%) and African American (59.4%), 
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Table 5. The most frequent co-existing diseases by race in Florida Medicare Beneficiaries with AD (N=5,879), 
2010 
 White (N=4,904) African American (N=394) Hispanic (N=581) 
Rank# Co-existing 
Disease 
N (%) Co-existing 
Disease 
N (%) Co-existing 
Disease 
N (%) 
1 Hypertension 3752 (76.5) Hypertension 323 (82) Hypertension 502 (86.4) 
2 Ischemic Heart 
Disease 2943 (60) Anemia 252 (64) 
Ischemic Heart 
Disease 436 (75) 
3 
Anemia 2693 (54.9) 
Ischemic Heart 
Disease 234 (59.4) RA/OAa 389 (67) 
4 Hyperlipidemia 2454 (50) Diabetes 203 (51.5) Anemia 370 (63.7) 
5 RA/OAa 2025 (41.3) Hyperlipidemia 191 (48.5) Hyperlipidemia 361 (62.1) 
Notes: AD: Alzheimer's Disease. 
# Rank is based on frequency of co-occurrences of a second disease. An individual record may have up to 20 
second diseases. 
a Rheumatoid Arthritis/ Osteoarthritis. 
 
Table 6 lists the top five diseases associated with 
highest mortality rate among 5,879 Florida Medicare 
Beneficiaries with AD by race. Three diseases in 
common for three race groups were Chronic Kidney 
Disease, Heart Failure, and Atrial Fibrillation. 
Among these diseases, the mortality rate associated 
with Chronic Kidney Disease did not differ much 
between White, African American and Hispanic AD 
patients (34.9%, 30.5%, 33.5%), so was the case with 
Heart Failure (32.7%, 26.8%, 28.3%), however, the 
mortality rate associated with Atrial Fibrillation was 
much higher among Hispanic AD patients (51.9%), 
than among White (28.7%) and African American 
(32.4%).  
Table 6. The co-existing disease with highest mortality rate, n(%), by race in Florida Medicare Beneficiaries with 
AD (N=5,879), 2010 
 White (N=4,904) African American (N=394) Hispanic (N=581) 
Rank# Co-existing 
Disease 








Mortality         
n (%) 
1 Chronic Kidney 
Disease 460 (34.9) 
COPDa and 
Bronchiectasis 21 (32.8) Atrial Fibrillation 27 (51.9) 
2 
Hip Fracture 70 (33.7) Atrial Fibrillation 12 (32.4) 
Chronic Kidney 
Disease 55 (33.5) 
3 
Heart Failure 596 (32.7) 
Chronic Kidney 
Disease 46 (30.5) Hip Fracture 4 (30.8) 
4 COPDa and 
Bronchiectasis 314 (29.9) Heart Failure 42 (26.8) 
Stroke/ Transient 
Ischemic Attack 20 (29) 
5 Atrial Fibrillation 207 (28.7) Cancer 9 (25.7) Heart Failure 72 (28.3) 
Notes: AD: Alzheimer's disease. 
# Rank is based on mortality rate given the presence of a second disease. An individual record may have up to 20 
second diseases. 
a Chronic Obstructive Pulmonary Disease.     
 
Table 7 lists the five most costly co-existing diseases 
among 5,879 Florida Medicare Beneficiaries with 
AD by race, ranked by average annual health care 
expenditure. Two diseases in common for three race 
groups were Hip Fracture, with lower cost among 
African American AD patients ($47,311) than among 
White ($60,588) and Hispanics ($59,126), and Atrial 
Fibrillation, with higher cost among African 
American ($52,232) and Hispanic ($57,652) than 




Hu and Carretta: Comorbidities of Medicare Beneficiaries with Alzheimer's Disease
Published by UNF Digital Commons,
 
HU & CARRETTA 6 
 
Table 7. The most costly co-existing disease by race in Florida Medicare Beneficiaries with AD (N=5,879), 2010 














Hip Fracture $60,588  
COPDa and 
Bronchiectasis $60,336  Hip Fracture $59,126  
2 COPDa and 
Bronchiectasis $40,501  Asthma $54,200  
Atrial 
Fibrillation $57,652  
3 
Asthma $40,298  
Atrial 
Fibrillation $52,232  
Stroke/ 
Transient 
Ischemic Attack $48,136  
4 Atrial 
Fibrillation $39,380  Hip Fracture $47,311  Cancer $45,549  
5 Chronic 
Kidney 
Disease $39,354  
Stroke/ 
Transient 
Ischemic Attack $45,605  
Chronic Kidney 
Disease $45,114  
Notes: AD: Alzheimer's disease. 
# Rank is based on expenditures given the presence of a second disease. An individual record may have up to 20 
second diseases. 
a Chronic Obstructive Pulmonary Disease. 
Discussion | PREVALENCE. While there are many 
articles about dementia including race as a risk factor, 
only a small number of studies (U.S. Department of 
Health and Human Services, 2014) focused on how 
prevalence of AD varies. In this study, the prevalence 
of AD was two times higher in Hispanics than in 
Whites, and 25.8% higher in African American than in 
Whites. The results in this study, agreed with previous 
studies (Tang, 1998; Alzheimer's Association, 2019, 
p.21) in that African-Americans and Hispanics were 
more likely than Whites to have a diagnosis of AD. In 
contrast to previous studies which suggested the 
highest risk of AD in African Americans, the present 
analyses showed that Hispanics had 2.4 times the risk 
of AD than African Americans among Florida older 
Medicare beneficiaries.  
 
In this study, the mean cost of total health care 
expenditure per person for beneficiaries with AD was 
found to be twice that of for beneficiaries in general 
($25,517 vs $12,717). Furthermore, among Florida 
Medicare beneficiaries with AD, the payments were 
12 percent higher for older African Americans, and 16 
percent higher for older Hispanics, than for older 
Whites. This finding is in line with Alzheimer’s 
association’s report (2019, p.57) that average 
Medicare Payment per person for beneficiaries 65 and 
older with a dementia diagnosis was higher for African 
American and Hispanics than for Whites in 2006.  
 
COMORBIDITY. A dementia diagnosis may reduce 
identification of co-existing chronic diseases such as 
Diabetes, as found in previous studies (Thorpe, 2012), 
and would accordingly detract from treatment of 
additional conditions (Fox, 2014). Patients with 
dementia were reported to have on average 2-8 
(Sanderson, 2002; Schubert, 2006) chronic conditions. 
Consistent with those estimates, the AD patients in the 
study sample had 5.8 (SD=	2.8) additional diseases on 
average.  
 
Despite the high prevalence of co-existing conditions, 
comorbidity of AD is largely understudied. Only a 
small number of studies (Duthie, 2011; Poblador-Plou, 
2014; Sanderson, 2002; Schubert, 2006; Thorpe, 
2012) emphasized the impact of certain conditions for 
AD patients. This study is one of the first to investigate 
the association between AD and a wide range of 
chronic conditions by race among Medicare 
beneficiaries in Florida. For each of 20 diseases, we 
screened the strength of the association (in terms of 
OR), the prevalence, the mortality rate, the average 
health care cost when it co-occurred with AD. In the 
following of the article, we focus on six major chronic 
conditions which were found to be either associated 
with highest risk AD, most frequently, or most costly 
when co-existing with AD: Heart Disease, Anemia, 
Depression, Hypertension, Hyperlipidemia, Chronic 
Kidney Disease, and Hip Fracture. 
 
HEART DISEASE. Heart disease screened in the 
present study includes several chronic conditions 
related to heart: Heart Failure, Ischemic heart Disease, 
and Atrial Fibrillation. The three heart disease 
conditions were associated with some of the highest 
degrees of co-occurrence, mortality, and high health 
care expenditures. The results in this study indicated 
heart disease not only showed a strong association 
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(heart failure) and a high prevalence (Ischemic Heart 
Disease) of co-occurrence with AD,  but also caused 
high mortality rate (Heart Failure, Atrial Fibrillation) 
and extremely high health care cost (Atrial 
Fibrillation) for AD patients, regardless of gender. The 
strong association between heart disease and 
dementia, AD, and/or cognitive impairment was noted 
frequently in previous studies (Justin, 2013; Newman, 
2005; Ott, 1997; Qiu, 2006; Soneira, 1996).  
 
HYPERTENSION, HYPERLIPIDEMIA. In 
previous literature, no consensus on the association 
between blood pressure and AD was determined. 
Some articles (Launer, 2000; Freitag, 2006; Skoog, 
1996) reported that elevated blood pressure in mid-life 
is a strong risk factor for dementia and/or AD, whereas 
other studies (Landin, 1993; Guo, 1996; Sanderson, 
2002) claimed that hypertension is associated with a 
reduced risk of AD.  
 
There is no clear picture from the literature about the 
association between Hyperlipidemia and AD either. 
Both positive (Solomon, 2009; Kivipelto, 2001) and 
negative (Reitz, 2004, 2010;Mielke, 2005) association 
between cholesterol and AD were previously reported. 
Some studies (Kalmijn, 2000; Tan, 2003) also 
suggested no significant association between the two.  
 
The finding in this study showed that Hypertension 
and Hyperlipidemia were both highly prevalent among 
2010 Florida older Medicare beneficiaries, especially 
for Hispanics. But Hypertension was found to be 
significantly associated with an increased risk of AD 
for White and Hispanic (1.74 (1.63, 1.86) for White, 
1.29 (0.99, 1.69) for African American, 1.65 (1.28, 
2.13) for Hispanic; data not shown), while 
Hyperlipidemia was significantly associated with a 
decreased risk of AD for White (OR= 0.62 (0.58, 
0.66), data not shown) and African American (0.73 
(0.59, 0.91); data not shown), but not for Hispanic 
(0.91 (0.76, 1.1); data not shown).   
 
ANEMIA. Research on the association between 
Anemia and dementia is scarce. In this study, the 
results showed Anemia was both highly prevalent 
among elder Medicare beneficiaries, and significantly 
associated with an increased risk of AD for all races. 
Previous studies (Beard, 1997; Hong, 2013) also have 
noted Anemia as a risk factor for dementia. One study 
by Sanderson et al. (2002) observed no significant 
association between Anemia and any dementia 
subtypes, possibly because their study sample 
included patients discharged with AD diagnosis from 
hospitals. Anemia, unlike other chronic conditions in 
this study, generally does not require hospitalization. 
Diet deficits among the elderly in general and the AD 
in particular are likely associated with these findings 
and may potentially be mitigated. 
 
DEPRESSION. In the results of this study, 
Depression was not among the top five in prevalence, 
but still highly prevalent among AD patients. This was 
especially true for Hispanic (49.4%), while White and 
African American beneficiaries with AD have a 
prevalence of 36% and 33% respectively. Depression 
was also significantly associated with an increased risk 
of AD regardless of race. This finding was supported 
by some studies which concluded that depression 
(Andersen, 2005; Saczynski, 2010; Geerlings, 2008; 
Green, 2003; Diniz, 2013) was a risk factor for later 
development of AD.   
 
CHRONIC KIDNEY DISEASE. Chronic Kidney 
Disease was found to be one of most deadly and costly 
comorbidities for beneficiaries with AD, with a 
prevalence of 26.9% for White, 38.3% for African 
Americans, and 28.2% for Hispanic.  
 
HIP FRACTURE. Even with a low prevalence among 
beneficiaries with AD (4.2% for White, 0.5% for 
African Americans, and 2.2% for Hispanic), Hip 
Fracture was found to be one of most costly 
comorbidities for beneficiaries with AD regardless of 
race. It was also associated with the highest mortality 
rate for White and Hispanic, but not for African 
American, at least in this study sample (mortality 
number is 0, data not shown). No deaths among 
African American beneficiaries with AD and a Hip 
Fracture were observed in this study.  
 
Limitations | The present study has several 
limitations. First, this study was based on a sample of 
fee-for-service Medicare beneficiaries in Florida in 
2010 and did not include any Medicare Advantage 
patients using private managed care companies. 
Approximately 32% (Centers for Medicare and 
Medicaid, 2012) of Florida Medicare beneficiaries 
were enrolled in Medicare Advantage in 2010. 
Medicare Part D drug claims were not available for 
analysis so the expenditure estimates only include 
medical treatments. The use of a 5% sample may have 
introduced some small differences in the point 
estimates as compared with a 100% sample which was 
not available for Carrier file claims.  Lastly, race and 
ethnicity are recorded in the Medicare data as a single 
variable and are based on self-report.  This may have 
led to classification errors in race and ethnicity 
categories. Findings from this study may not be 
generalizable to other states or years. 
 
Implications | Comorbidities may exacerbate the 
development of AD (Solomon, 2011). In addition, the 
presence of AD may adversely affect the management 
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of co-existing conditions (Thorpe, 2012). However, 
only a small number of studies have focused on 
comorbidities associated with AD. The findings from 
this study have important implications for healthcare 
providers, public health professionals, and policy 
makers interested in the treatment and control of 
Alzheimer’s disease.    
 
In this study, we find that three types of heart diseases 
(Heart Failure, Ischemic heart Disease, Atrial 
Fibrillation) were most prevalent, most deadly, and 
most costly co-existing conditions among 
beneficiaries with AD. Hypertension and 
Hyperlipidemia were two of most prevalent 
comorbidities among beneficiaries with AD. Research 
on association between Anemia and AD is scarce. 
According to this study, Anemia is both highly 
prevalent, and significantly associated with an 
increased risk of AD for all races. This is plausibly due 
to poor diet among the AD population, but no literature 
was identified directly supporting this speculation. 
Depression is also significantly associated with an 
increased risk of AD regardless of race. Chronic 
Kidney Disease is one of most deadly and costly 
comorbidities for beneficiaries with AD. With a low 
prevalence, Hip Fracture is one of most costly 
comorbidities for beneficiaries with AD. Give a lack 
of studies in this field, more efforts are called for to 
look into the impact, quality of control, and 
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